Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations

U. Schara, N. Barisic, M. Deschauer, C. Lindberg, V. Straub, N. Strigl-Pill, M. Wendt, A. Abicht, J. S. Müller, H. Lochmüller

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

In congenital myasthenic syndrome with DOK7 mutations ephedrine was reported to be beneficial in single patients. We carried out a small, open and prospective cohort study in eight European patients manifesting from birth to 12 years. Five patients showed limb-girdle and facial weakness, three a floppy infant syndrome with bulbar symptoms and/or respiratory distress. Ephedrine was started with 25 mg/day and slowly increased to 75-100 mg/day. Within weeks after starting therapy an improvement was observed in all patients and clinical follow-up disclosed positive effects more pronounced on proximal muscle weakness and strength using MRC scale. Effects on facial weakness were less pronounced. Vital capacity measurements and repetitive stimulation tests did not improve in the same way as clinical symptoms did. These investigations are appropriate to confirm the diagnosis in case of pathological results, but they might not be appropriate means to monitor patients under ephedrine therapy.

Original languageEnglish
Pages (from-to)828-832
Number of pages5
JournalNeuromuscular Disorders
Volume19
Issue number12
DOIs
StatePublished - Dec 2009
Externally publishedYes

Keywords

  • Congenital myasthenic syndrome
  • DOK7
  • Downstream-of-kinase-7
  • Ephedrine therapy
  • Synaptopathy

Fingerprint

Dive into the research topics of 'Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations'. Together they form a unique fingerprint.

Cite this